Insider Selling: Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Director Sells $194,172.30 in Stock

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Director Jacqualyn A. Fouse sold 7,497 shares of the stock in a transaction dated Thursday, April 10th. The stock was sold at an average price of $25.90, for a total transaction of $194,172.30. Following the sale, the director now owns 149,220 shares of the company’s stock, valued at $3,864,798. This trade represents a 4.78 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Agios Pharmaceuticals Stock Performance

Shares of AGIO opened at $26.70 on Friday. The company has a market capitalization of $1.53 billion, a PE ratio of 2.35 and a beta of 0.83. The stock has a fifty day moving average of $31.39 and a two-hundred day moving average of $39.24. Agios Pharmaceuticals, Inc. has a fifty-two week low of $23.42 and a fifty-two week high of $62.58.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share for the quarter, missing the consensus estimate of ($1.69) by ($0.05). Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. As a group, equities research analysts forecast that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently weighed in on AGIO shares. StockNews.com downgraded Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, February 14th. HC Wainwright assumed coverage on Agios Pharmaceuticals in a report on Monday, February 24th. They issued a “buy” rating and a $58.00 price target on the stock. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Agios Pharmaceuticals in a report on Wednesday, December 18th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $56.57.

Institutional Trading of Agios Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the stock. FMR LLC boosted its position in shares of Agios Pharmaceuticals by 283.2% during the third quarter. FMR LLC now owns 45,393 shares of the biopharmaceutical company’s stock worth $2,017,000 after buying an additional 33,546 shares during the period. BNP Paribas Financial Markets boosted its holdings in shares of Agios Pharmaceuticals by 15.1% during the third quarter. BNP Paribas Financial Markets now owns 11,946 shares of the biopharmaceutical company’s stock worth $531,000 after purchasing an additional 1,570 shares during the period. Verition Fund Management LLC purchased a new position in Agios Pharmaceuticals in the third quarter valued at about $315,000. State Street Corp increased its stake in shares of Agios Pharmaceuticals by 10.2% during the 3rd quarter. State Street Corp now owns 2,331,433 shares of the biopharmaceutical company’s stock worth $103,586,000 after purchasing an additional 216,484 shares during the last quarter. Finally, XTX Topco Ltd increased its stake in shares of Agios Pharmaceuticals by 56.2% in the third quarter. XTX Topco Ltd now owns 8,329 shares of the biopharmaceutical company’s stock worth $370,000 after purchasing an additional 2,996 shares during the period.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.